MedCity News November 12, 2024
As radiopharmaceuticals enter a new phase, industry leaders must rethink external services and internal capabilities to master the complexities of delivering advanced therapies.
The radioligand therapy (RLT) space is entering a new era, as demonstrated by Eli Lilly’s recent $4.5 billion investment in a new research and manufacturing infrastructure. Pharmaceutical companies, typically focused on the development of intellectual property, are increasingly prioritizing their ability to produce, scale, and deliver these innovative treatments. Novartis has also doubled down on this shift, with an additional $200 million investment in the manufacturing of RLT and accompanying customer services. Together, these investments underscore the industry’s evolution towards mastering the intricate processes required for widespread RLT adoption, marking a new chapter in personalized cancer treatment.
...Today's Sponsors
Today's Sponsor